Sino Biopharmaceutical’s KRAS Inhibitor Garsorasib Earns Breakthrough Designation in China
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has announced that its...
Sansure Biotech’s Tuberculosis Detection Kit Gains CE IVDR Certification for EU Market
Sansure Biotech Inc. (SHA: 688289), a leading molecular diagnostics company based in China, has announced...
Ascentage Pharma Gets Green Light for Global Phase III Trial of Olverembatinib in SDH-Deficient GIST
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
Kyowa Kirin to Invest $530 Million in US Biologics Factory for Rare Disease Therapies
Japanese pharmaceutical company Kyowa Kirin (TYO: 4151) has unveiled plans for a substantial investment of...
Johnson & Johnson to Acquire Biotechnology Firm Yellow Jersey for $1.25 Billion
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has entered into a definitive...
Bayer’s HER2 Targeting Drug BAY 2927088 Earns Breakthrough Designation in China
The Center for Drug Evaluation (CDE) in China has granted Breakthrough Therapy Designation (BTD) to...
China’s CDE Opens Consultation on 83rd Batch of Generic Chemical Reference Preparations
The Center for Drug Evaluation (CDE), a key regulatory body in China, is currently in...
InnoCare Pharma’s TYK2 Inhibitor ICP-332 Receives FDA IND Approval for Atopic Dermatitis
InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company based in China has announced that...
China’s NMPA Unveils Three-Year Smart Supervision Plan for Blood Product Industry
China’s National Medical Products Administration (NMPA) has unveiled the “Three-Year Action Plan for Smart Supervision...
Recorna and Starna Therapeutics Join Forces to Advance RNA Gene Editing in Lung Diseases
Recorna (Guangzhou) Biotechnology Co., Ltd, a pioneering RNA editing therapy startup based in China, has...
Novartis’s Tabrecta Earns NMPA Nod for MET-Positive Advanced NSCLC in China
Swiss pharmaceutical titan Novartis has secured marketing approval from China’s National Medical Products Administration (NMPA)...
Biosion’s Bosakitug Shows Positive Results in Atopic Dermatitis Phase II POC Study
Biosion, a clinical-stage biotechnology company with operations in Delaware, U.S., and China, has announced key...
Ascletis Pharma’s ASC41 Shows Promise in Phase II Study for Metabolic Dysfunction-Associated Steatohepatitis
Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced positive interim...
China Medical System Secures Exclusive Rights to Baiyiyuan Biotech’s Implant in Greater China
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with Shanghai-based...
Shanghai Pharmaceuticals Halts Development of B001 and I022 for Selected Indications
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced the discontinuation of clinical studies and...
Shanghai Turtle Technology Partners with Focusgen Biotech to Advance Tumor Liquid Biopsy Innovations
Shanghai Turtle Technology Co., Ltd, a leading Polymerase Chain Reaction (PCR) specialist in China, has...
Brii Biosciences’ BRII-179 Shows Promise in Phase II Trials for Chronic Hepatitis B at EASL 2024
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has presented new...
AI-Powered Biotech Insilico Medicine Initiates Phase I Clinical Trial for Inflammatory Bowel Disease Drug
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
China’s NMPA Issues New Supervision Measures for Medical Device Clinical Trials Starting October 2024
The National Medical Products Administration (NMPA) has approved the “Measures for Supervision and Inspection of...
Jiangxi Fushine’s Subsidiary LinkChem Eyes Hong Kong IPO Amid Strong Revenue Growth
Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE: 300497), a Chinese pharmaceutical company, has announced that its...